Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 141
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT05831111 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | ||
| NCT04813796 | A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19 | ||
| NCT03345043 | Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects | ||
| NCT04144348 | Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure | ||
| NCT05992935 | Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age | ||
| NCT05398796 | Dose Escalation, Open-Label Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine, mRNA-1215, in Healthy Adults | ||
| NCT06097273 | A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age | ||
| NCT05831787 | COVID19 OutcomeS in Myeloma and the Impact of VaCcines | ||
| NCT05533697 | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | ||
| NCT06508320 | A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine) | ||
| NCT05333289 | A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults | ||
| NCT06646406 | Evaluation of a Multilevel Intervention on Adult COVID-19 and Influenza Vaccination Rate | ||
| NCT05975099 | A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age | ||
| NCT05001373 | A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core) | ||
| NCT06143046 | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers | ||
| NCT05765578 | An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5) | ||
| NCT04649151 | A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19 | ||
| NCT05130437 | A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study | ||
| NCT05827068 | A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults | ||
| NCT05933577 | A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001) | ||
| NCT06295809 | A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) | ||
| NCT05572658 | Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study | ||
| NCT07513376 | A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014) | ||
| NCT05585632 | A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old | ||
| NCT03897881 | An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | ||
| NCT05606965 | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults | ||
| NCT05414786 | A Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) | ||
| NCT05683457 | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants. | ||
| NCT06864143 | A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age | ||
| NCT05894499 | Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19 | ||
| NCT04899310 | A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia | ||
| NCT06585241 | A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations | ||
| NCT04064905 | Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults | ||
| NCT03810690 | Open Label Study of mRNA-3704 in Patients With Isolated Methylmalonic Acidemia | ||
| NCT04796896 | A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age | ||
| NCT06033261 | A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes | ||
| NCT03325075 | Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Participants | ||
| NCT06522880 | Cytomegalovirus (CMV) Transmission and Immune Tracking (TransmIT) Study | ||
| NCT05127434 | A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age | ||
| NCT06097299 | A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus | ||
| NCT05249829 | A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19 | ||
| NCT06305767 | A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005) | ||
| NCT05383560 | Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults | ||
| NCT06602024 | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age | ||
| NCT04232280 | Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults | ||
| NCT04927065 | A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants | ||
| NCT05054218 | COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients | ||
| NCT05794412 | Mucosal Immunity: Influence on Infectious Viral Load: a Prospective Observational Study | ||
| NCT06369272 | Study to Assess Maternal and Infant Outcomes Following Exposure to SPIKEVAX During Pregnancy | ||
| NCT06147856 | A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria |
